|
Par Pharmaceutical Companies, Inc.™ develops, manufactures, markets and distributes high-quality pharmaceuticals through two divisions:
Par Pharmaceutical
, our generic drug division, and
Strativa Pharmaceuticals
, our proprietary products division. We combine the energy and innovation of a new venture with the fully integrated resources of a leading, diversified pharmaceutical company.
-
Founded as a generics products company in 1978. Today includes two divisions:
- Employs more than 600 professionals in offices in Woodcliff Lake, New Jersey (Corporate Headquarters), Spring Valley, New Yor...
More >> |
| Date | Title | | 05/08/13 | Par Pharmaceutical Announces Quarterly Conference Call| Woodcliff Lake, N.J., May 8, 2013 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, May 16, 2013, at 10:00 a.m. EDT to review its results of operations for the quarter ended March 31, 2013. Par is privately held and does not generally make its financial information available to the public. However, holders of Par’s debt securities, certain prospective holders of Par’s debt securities and research analysts who cover or intend to cov... |
| | 04/01/13 | NJBIZ Honors New Jersey’s General Counsels| Par’s Martin Wilson Among Finalists
Woodcliff Lake, NJ, April 1, 2013 – Martin L. Wilson, Chief Counsel, Compliance & Litigation, has been named a finalist in the Corporate Compliance Professional category in the 2013 NJBIZ General Counsel of the Year Awards program. The award program, produced by NJBIZ, New Jersey’s premiere business news publication, is sponsored by Nicoll Davis & Spinella LLP, Real Estate Strategies, Update Discovery, Gibbons P.C., Arch... |
| | 03/14/13 | Par Pharmaceutical Begins Shipment of Generic Luvox CR®| Company Awarded 180 Days Marketing Exclusivity for 150 mg Strength
Woodcliff Lake, NJ, March 14, 2013 – Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for fluvoxamine maleate 100 mg and 150 mg extended-release (ER) capsules. Fluvoxamine maleate ER is the generic version of Jazz Pharmaceuticals’ Luvox CR® and is indicated for the treatment of obsessive compulsi... |
| | 03/11/13 | Par Pharmaceutical Announces Quarterly Conference Call| Woodcliff Lake, N.J., March 11, 2013 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, March 21, 2013, at 10:00 A.M. EDT to review its results of operations for the year ended December 31, 2012. Par is privately held and does not generally make its financial information available to the public. However, holders of Par’s debt securities, certain prospective holders of Par’s debt securities and research analys... |
|
|
|
| There are currently no events scheduled. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
|
